These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
503 related articles for article (PubMed ID: 32101780)
21. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease. Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866 [TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease. Weinreb O; Amit T; Bar-Am O; Youdim MB Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830 [TBL] [Abstract][Full Text] [Related]
23. Alzheimer's disease: emerging trends in small molecule therapies. Mohamed T; Rao PP Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820 [TBL] [Abstract][Full Text] [Related]
24. Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, β-secretase, and amyloid β aggregation as potential treatment of Alzheimer's disease. Zaręba P; Łątka K; Mazur G; Gryzło B; Pasieka A; Godyń J; Panek D; Skrzypczak-Wiercioch A; Höfner GC; Latacz G; Maj M; Espargaró A; Sabaté R; Jóźwiak K; Wanner KT; Sałat K; Malawska B; Kulig K; Bajda M Eur J Med Chem; 2023 Dec; 261():115832. PubMed ID: 37837674 [TBL] [Abstract][Full Text] [Related]
25. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production. Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Luo X; Yan R Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410 [TBL] [Abstract][Full Text] [Related]
27. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. Das B; Yan R CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576 [TBL] [Abstract][Full Text] [Related]
28. BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives. Coimbra JRM; Resende R; Custódio JBA; Salvador JAR; Santos AE J Alzheimers Dis; 2024; 101(s1):S53-S78. PubMed ID: 38943390 [TBL] [Abstract][Full Text] [Related]
29. Editorial: Multitarget Molecules for Alzheimer's Disease Therapy. Marco-Contelles J; Fall Y Curr Top Med Chem; 2017; 17(31):3318. PubMed ID: 29500890 [No Abstract] [Full Text] [Related]
30. Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation. Tian C; Qiang X; Song Q; Cao Z; Ye C; He Y; Deng Y; Zhang L Bioorg Chem; 2020 Jan; 94():103477. PubMed ID: 31818478 [TBL] [Abstract][Full Text] [Related]
31. Potential therapeutic agents against Alzheimer's disease from natural sources. Park SY Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936 [TBL] [Abstract][Full Text] [Related]
32. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease. Read J; Suphioglu C Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717 [TBL] [Abstract][Full Text] [Related]
33. A short peptide from sAPPα binding to BACE1-APP action site rescues Alzheimer-like pathology. Lai X; Hu J; Liu H; Lan L; Long Y; Gao X; Deng J Neurosci Lett; 2022 Jan; 770():136397. PubMed ID: 34915100 [TBL] [Abstract][Full Text] [Related]
34. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411 [TBL] [Abstract][Full Text] [Related]
35. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors. Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442 [TBL] [Abstract][Full Text] [Related]
36. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Moussa CE Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311 [TBL] [Abstract][Full Text] [Related]
37. Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach. Dorababu A Bioorg Chem; 2019 Dec; 93():103299. PubMed ID: 31586701 [TBL] [Abstract][Full Text] [Related]
38. Investigational BACE inhibitors for the treatment of Alzheimer's disease. Imbimbo BP; Watling M Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331 [No Abstract] [Full Text] [Related]
39. The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review. Ahmad SS; Khan S; Kamal MA; Wasi U CNS Neurol Disord Drug Targets; 2019; 18(9):657-667. PubMed ID: 31608840 [TBL] [Abstract][Full Text] [Related]
40. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases. Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]